Abstract
Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Current Drug Metabolism
Title: The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Volume: 9 Issue: 8
Author(s): M. N. Jacobs, W. Janssens, U. Bernauer, E. Brandon, S. Coecke, R. Combes, P. Edwards, A. Freidig, A. Freyberger, R. Kolanczyk, C. Mc Ardle, O. Mekenyan, P. Schmieder, T. Schrader, M. Takeyoshi and B. van der Burg
Affiliation:
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Abstract: Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Export Options
About this article
Cite this article as:
Jacobs N. M., Janssens W., Bernauer U., Brandon E., Coecke S., Combes R., Edwards P., Freidig A., Freyberger A., Kolanczyk R., Mc Ardle C., Mekenyan O., Schmieder P., Schrader T., Takeyoshi M. and Burg van der B., The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors, Current Drug Metabolism 2008; 9 (8) . https://dx.doi.org/10.2174/138920008786049294
DOI https://dx.doi.org/10.2174/138920008786049294 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Impact of brain tissue binding and plasma protein binding of drugs in DMPK
The impression of brain tissue binding (BTB) or plasma protein binding (PPB) in Drug Metabolism and Pharmacokinetics is critical to understanding the distribution, efficacy, and potential toxicity of drugs that target the central nervous system (CNS). BTB and high PPB influence the distribution of drugs in the body and their ...read more
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Metabolism-Mediated Xenobiotic Toxicity
Considering the potent modulation of biotransformation enzyme expression and activities by various therapeutic drugs and environmental chemicals, and the commonly combined exposure of humans to both drugs and the ever increasing environmental pollutants simultaneously, knowledge about the combined toxic effects by modulating biotransformation enzymes, such as P450s, UDP- glucuronosyltransferases, and ...read more
Safety evaluation of vaccine combination
Vaccine combination safety evaluation is a critical field within immunology and public health that focuses on assessing the safety and efficacy of combining different vaccines to maximize protection against various diseases while minimizing potential adverse effects. This process is significant because it ensures that vaccines can be administered together without ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insights on the Xenobiotic-Sensing Nuclear Receptors in Liver Diseases – CAR and PXR-
Current Drug Metabolism DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Analysis of Drug Transport Kinetics in Multidrug-resistant Cells: Implications for Drug Action
Current Medicinal Chemistry Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Non-Analgesic Effects of Opioids: Mechanisms and Potential Clinical Relevance of Opioid-Induced Immunodepression
Current Pharmaceutical Design Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science In Vitro Anticancer Effects of Two New Potent Hydrazide Compounds on Leukemic Cells
Anti-Cancer Agents in Medicinal Chemistry Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Adrenomedullin Expression in Alzheimer's Brain
Current Alzheimer Research Cytotoxic Effect of 5-Fluorouracil-loaded Polymer-coated Magnetite Nanographene Oxide Combined with Radiofrequency
Anti-Cancer Agents in Medicinal Chemistry The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress
Current Neuropharmacology Cellular Therapy for Treatment of Stress Urinary Incontinence
Current Stem Cell Research & Therapy Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Toll-like Receptors as a Novel Therapeutic Target for Natural Products Against Chronic Diseases
Current Drug Targets KF/Clinoptilolite Nanoparticles as a Heterogeneous Catalyst for Green Synthesis of pyrido[2,1-a]isoquinolines using Four-Component Reaction of Alkyl Bromides
Combinatorial Chemistry & High Throughput Screening Digital Mammograms with Image Enhancement Techniques for Breast Cancer Detection: A Systematic Review
Current Medical Imaging Application of Diet-derived Taste Active Components for Clinical Nutrition: Perspectives from Ancient AyurvedicMedical Science, Space Medicine, and Modern Clinical Nutrition
Current Pharmaceutical Design